COMPASS Pathways plc (ADR)
General ticker "CMPS" information:
- Sector: Health Care
- Industry: Medical - Care Facilities
- Capitalization: $624.8M (TTM average)
COMPASS Pathways plc (ADR) follows the US Stock Market performance with the rate: 57.7%.
Estimated limits based on current volatility of 5.1%: low 13.09$, high 14.49$
Factors to consider:
- Total employees count: 156 (-6.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Commercialization failure, Regulatory and compliance, Key person loss, Cybersecurity threats
- Current price 18.7% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.76$, 10.82$]
- 2026-12-31 to 2027-12-31 estimated range: [2.72$, 8.23$]
Financial Metrics affecting the CMPS estimates:
- Positive: with PPE of -3.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Interest expense per share per price, % of 0.73 <= 0.74
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -25.12 <= 19.19
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -0.03 < Industry operating cash flow per share per price (median), % of 4.90
- Positive: Inventory ratio change, % of 0 <= 0
Short-term CMPS quotes
Long-term CMPS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $136.92MM | $178.21MM | $179.04MM |
| Operating Income | $-136.92MM | $-178.21MM | $-179.04MM |
| Non-Operating Income | $19.23MM | $24.68MM | $-111.30MM |
| Interest Expense | $2.20MM | $4.48MM | $4.52MM |
| R&D Expense | $87.52MM | $119.04MM | $118.44MM |
| Income(Loss) | $-117.68MM | $-153.53MM | $-290.33MM |
| Taxes | $0.78MM | $1.59MM | $-2.47MM |
| Net Income(Loss)* | $-118.46MM | $-155.12MM | $-287.86MM |
| Stockholders Equity | $225.74MM | $154.69MM | $-52.85MM |
| Assets | $275.99MM | $213.67MM | $210.35MM |
| Operating Cash Flow | $-97.38MM | $-119.19MM | $-157.24MM |
| Capital expenditure | $0.07MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.06MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $173.83MM | $63.82MM | $140.71MM |
| Earnings Per Share** | $-2.32 | $-2.30 | $-3.08 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.